Co-Processed Excipients Help Formulate Better OSDs

Co-processed excipients are expected to play a key role in the production of new chemical entities (NCEs), according to BCC Research. As developing new excipients can be time-consuming and expensive from a safety perspective, manufacturers see co-processing of already approved excipients as an attractive alternative. These excipients are engineered to achieve the properties of the key components of the tableting blend in a single, highly flowable and compressible granular material.1 As a result, where there were less than a handful of co-processed excipients on the market 15 or 20 years ago, there now are more than 20 that are commercially available to formulators, and it is very likely that this number will continue to grow.

http://www.pharmamanufacturing.com/articles/2017/co-processed-excipients-help-formulate-better-osds/